Neurogene and Behind the Seizure Work to Provide Better Diagnostics for Batten Disease
source: pixabay.com

Neurogene and Behind the Seizure Work to Provide Better Diagnostics for Batten Disease

Neurogene, which works to provide treatments for rare neurological disorders, has recently joined with Behind the Seizure. Behind the Seizure was established by two other companies, BioMarin and Invitae, with…

Continue Reading Neurogene and Behind the Seizure Work to Provide Better Diagnostics for Batten Disease
Study Tracks Survival, Quality of Life, and Follow up for Lambert-Eaton Myasthenic Syndrome Patients
source: pixabay.com

Study Tracks Survival, Quality of Life, and Follow up for Lambert-Eaton Myasthenic Syndrome Patients

According to a study published in the scientific journal Neurology, the survival rates of patients with Lambert-Eaton myasthenic syndrome (LEMS) were compared to that of the general population as well as…

Continue Reading Study Tracks Survival, Quality of Life, and Follow up for Lambert-Eaton Myasthenic Syndrome Patients
An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit
source: pixabay.com

An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit

  On February 3, 2020, twenty-seven newly installed flags of the European Union stood in the gleaming lobby of the new European Medicines Agency (EMA) headquarters in Amsterdam. The Charcot-Marie-Tooth…

Continue Reading An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit
The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases
source: pixabay.com

The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases

According to a story from Charcot-Marie-Tooth News, the Muscular Dystrophy Association (MDA) may at first seem like a group that is solely focused on helping muscular dystrophy patients, but its…

Continue Reading The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases
Expanding AAV Manufacturing Capacity is Essential to Our Ability to Cure More Patients Living with Rare Disease
source: pixabay.com

Expanding AAV Manufacturing Capacity is Essential to Our Ability to Cure More Patients Living with Rare Disease

  The National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the Center for Biologics Evaluation and Research (CBER) of the Food and Drug…

Continue Reading Expanding AAV Manufacturing Capacity is Essential to Our Ability to Cure More Patients Living with Rare Disease
Losmapimod Receives Orphan Drug Designation for the Treatment of FSHD
source: pixabay.com

Losmapimod Receives Orphan Drug Designation for the Treatment of FSHD

Losmapimod is an experimental treatment for facioscapulohumeral muscular dystrophy (FSHD), and it recently received the Orphan Drug designation from the FDA. Not only did it receive this designation, but its…

Continue Reading Losmapimod Receives Orphan Drug Designation for the Treatment of FSHD
He Didn’t Want to Miss his Daughter’s First Birthday, so he Campaigned for a Cure for ALS
source: pixabay.com

He Didn’t Want to Miss his Daughter’s First Birthday, so he Campaigned for a Cure for ALS

As originally reported in ArcaMax,  when you get a diagnosis for a terminal rare disease, a wave of emotions crashes over life. Brian Wallach emerged clutching 'hope.' In 2017, Brian,…

Continue Reading He Didn’t Want to Miss his Daughter’s First Birthday, so he Campaigned for a Cure for ALS
Does the ‘Quality Adjusted Life Year’ Measure Leave Behind Rare Disease Patients?
source: pixabay.com

Does the ‘Quality Adjusted Life Year’ Measure Leave Behind Rare Disease Patients?

According to a story from Salon, the Quality Adjusted Life Year (QALY) is a statistical measure that is used in order to calculate the value of a certain medication. First…

Continue Reading Does the ‘Quality Adjusted Life Year’ Measure Leave Behind Rare Disease Patients?
Venclyxto® Plus Obinutuzumab Offers Previously Untreated CLL Patients Chemotherapy-Free Treatment
source: pixabay.com

Venclyxto® Plus Obinutuzumab Offers Previously Untreated CLL Patients Chemotherapy-Free Treatment

  A recent press release by the global biopharmaceutical research company, AbbVie, reported a positive opinion by CHMP granted to VENCLYXTO® combined with obinutuzumab to treat chronic lymphocytic leukemia (CLL). A positive opinion by…

Continue Reading Venclyxto® Plus Obinutuzumab Offers Previously Untreated CLL Patients Chemotherapy-Free Treatment